Literature DB >> 16210656

V gamma 9V delta 2 T cell response to colon carcinoma cells.

Murielle Corvaisier1, Agnès Moreau-Aubry, Elisabeth Diez, Jaafar Bennouna, Jean-Francois Mosnier, Emmanuel Scotet, Marc Bonneville, Francine Jotereau.   

Abstract

During analysis of CD8 T cells derived from ascites of a colon cancer patient, we isolated a Vgamma9Vdelta2 T cell clone showing strong reactivity against autologous tumor cell lines. This clone killed a large fraction of allogeneic colon carcinoma and melanoma cell lines, but did not affect a normal colon cell line, colon fibroblasts, or melanocytes. Tumor cell recognition was TCR and NKG2D dependent and induced TNF-alpha and IFN-gamma secretion by the clone; accordingly, tumor targets expressed several NKG2D ligands, such as MHC class I chain-related gene A and UL16-binding protein molecules. Colon tumor recognition by Vgamma9Vdelta2 T cells was highly dependent on isopentenyl pyrophosphate production and ICAM-1 expression by target cells. Finally, similar reactivity patterns against colon carcinoma cell lines were observed using polyclonal Vgamma9Vdelta2 T cells of various origins, and Vgamma9Vdelta2 lymphocytes were present in the majority of colon tumor samples studied. Together, these results suggest that Vgamma9Vdelta2 T cells contribute to the natural immune surveillance against colon cancers. Therefore, this study provides a strong rationale for the use of Vgamma9Vdelta2 T cell agonists in immunotherapies targeting colon tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210656     DOI: 10.4049/jimmunol.175.8.5481

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  77 in total

Review 1.  Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity.

Authors:  Marc Bonneville; Rebecca L O'Brien; Willi K Born
Journal:  Nat Rev Immunol       Date:  2010-06-11       Impact factor: 53.106

2.  γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Authors:  Mounia Sabrina Braza; Bernard Klein; Geneviève Fiol; Jean-François Rossi
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 3.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Authors:  Hamid Reza Mirzaei; Hamed Mirzaei; Sang Yun Lee; Jamshid Hadjati; Brian G Till
Journal:  Cancer Lett       Date:  2016-07-05       Impact factor: 8.679

4.  Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens.

Authors:  Andrew M Hebbeler; Cristiana Cairo; Jean Saville Cummings; C David Pauza
Journal:  Cancer Immunol Immunother       Date:  2006-11-28       Impact factor: 6.968

5.  Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.

Authors:  Maria Raffaella Zocchi; Delfina Costa; Roberta Venè; Francesca Tosetti; Nicoletta Ferrari; Simona Minghelli; Roberto Benelli; Stefano Scabini; Emanuele Romairone; Silvia Catellani; Aldo Profumo; Alessandro Poggi
Journal:  Oncoimmunology       Date:  2017-01-06       Impact factor: 8.110

6.  Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vgamma2Vdelta2 T cells in macaques.

Authors:  Zahida Ali; Lingyun Shao; Lisa Halliday; Armin Reichenberg; Martin Hintz; Hassan Jomaa; Zheng W Chen
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

Review 7.  Role of apolipoproteins in gammadelta and NKT cell-mediated innate immunity.

Authors:  Eric Champagne; Laurent O Martinez; Pierre Vantourout; Xavier Collet; Ronald Barbaras
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

8.  Signal transduction by different forms of the γδ T cell-specific pattern recognition receptor WC1.

Authors:  Chuang Chen; Haoting Hsu; Edward Hudgens; Janice C Telfer; Cynthia L Baldwin
Journal:  J Immunol       Date:  2014-05-21       Impact factor: 5.422

Review 9.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

10.  Gammadelta T cell immune manipulation during chronic phase of simian-human immunodeficiency virus infection [corrected] confers immunological benefits.

Authors:  Zahida Ali; Lin Yan; Nicholas Plagman; Armin Reichenberg; Martin Hintz; Hassan Jomaa; Francois Villinger; Zheng W Chen
Journal:  J Immunol       Date:  2009-09-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.